NCT02654470 is a clinical trial of Watchman FLX in Non-valvular Atrial Fibrillation, sponsored by Boston Scientific Corporation.

Who is sponsoring NCT02654470?

NCT02654470 is sponsored by Boston Scientific Corporation.

What drugs are being tested in NCT02654470?

Interventions in NCT02654470: Watchman FLX.

What condition does NCT02654470 study?

NCT02654470 studies Non-valvular Atrial Fibrillation.

Is NCT02654470 still recruiting?

NCT02654470 is currently completed. Last updated 19 November 2021.

Last reviewed 2021-11-19 · How we verify

NCT02654470

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Watchman FLX Left Atrial Appendage Closure Device Post Approval Study ( Europe Only)

Completed Last updated 19 November 2021

What this trial tests

trial testing Watchman FLX in Non-valvular Atrial Fibrillation in 300 participants. Completed in 28 September 2021.

Timeline

16 July 2019

Primary endpoint
28 September 2021

28 September 2021

Quick facts

Lead sponsor	Boston Scientific Corporation
Status	Completed
Study type	OBSERVATIONAL
Enrollment	300
Start date	16 July 2019
Primary completion	28 September 2021
Estimated completion	28 September 2021
Sites	17 locations across Denmark, France, Italy, Netherlands, Ireland, United Kingdom, Germany, Poland

Drugs / interventions tested

Watchman FLX

Conditions studied

Non-valvular Atrial Fibrillation — all drugs for Non-valvular Atrial Fibrillation →

Sponsor

Boston Scientific Corporation — full company profile →

Who can join

18 and older, any sex, with Non-valvular Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Watchman FLX Left Atrial Appendage Closure Device Post Approval Study

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Real-world clinical outcomes with a next-generation left atrial appendage closure device: the FLXibility Post-Approval Study.
Betts TR, Grygier M, Nielsen Kudsk JE, Schmitz T, et al · · 2023 · cited 25× · PMID 36734247 · DOI 10.1093/europace/euac270

Verify or expand the search:

Other recruiting trials for Non-valvular Atrial Fibrillation

Currently open trials in the same condition.

NCT05565599 — An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Sub · NA · active not recruiting

Other Boston Scientific Corporation trials

Trials by the same sponsor.

NCT07458243 — Registry of ENROUTE NPS in Conjunction With Carotid WALLSTENT · not yet recruiting
NCT07458217 — Combined CM and STN Stimulation for Motor Epilepsy · NA · not yet recruiting
NCT07276815 — OverStitch NXT Endoscopic Suture System · NA · not yet recruiting
NCT07353710 — A Study on the Acquisition of 2D ICE Images With the CHORUS IDx System in Subjects Undergoing an Ablation Procedure · NA · not yet recruiting
NCT07195708 — Orbera365 Intragastric Balloon System (Abbreviated as'Orbera365') · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02654470 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boston Scientific Corporation
Last refreshed: 19 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02654470.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing